Delcath CHEMOSAT Gains ESMO Guideline Recognition Boost
Queensbury, New York, USA, April 6, 2026 ESMO Guideline Inclusion Validates CHEMOSAT Therapy In a major milestone for interventional...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Queensbury, New York, USA, April 6, 2026 ESMO Guideline Inclusion Validates CHEMOSAT Therapy In a major milestone for interventional...
QUEENSBURY, NEW YORK | December 31, 2025 — Delcath Systems announced the peer-reviewed publication of prespecified subgroup analyses from...
